Replimune Group Inc diskutieren
Replimune Group Inc
WKN: A2JQN1 / Symbol: REPL / Name: Replimune Group / Aktie / Small Cap /
?
0,00 %
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $19.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target lowered by analysts at Jefferies Financial Group Inc. from $31.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to an "underperform" rating. They now have a $2.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $18.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $13.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $13.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Neueste Beiträge
Cowen_Inc in Rhythm Pharmaceuticals diskutieren